* SUBJECT INCLUSION CRITERIA:
Healthy women and men will be eligible for study participation if they meet the following criteria:
* A participant will have passed his/her 18th birthday and will not have attained the age of 50 at the time of enrollment.
* Willing to allow storage of their biological samples.
* Able to comply with study procedures and swallow capsules.
SUBJECT EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from study participation:
* Body Mass Index (BMI) greater than or equal to 35 or less than or equal to 18 kg/M(2).
* Vital signs outside of acceptable range at Screening Visit, i.e., blood pressure \>160/100, oral temperature \>100 degrees F, pulse \>100.
* Use of any of the following drugs or devices within the last 6 months:
* systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral);
* oral, intravenous, intramuscular, nasal, or inhaled corticosteroids;
* cytokines;
* methotrexate or immunosuppressive cytotoxic agents;
* large doses of commercial probiotics consumed (greater than or equal to 10(8) cfu or organisms per day), including tablets, capsules, lozenges, chewing gum, or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, and foods do not apply.
* anabolic steroids;
* intrauterine device, combination hormone vaginal ring for contraception (due to unknown duration of local hormone effects), topical or systemic estrogens. Oral contraceptives with a standard 28-day cycle will be permitted if the subject has been consistently taking them for at least 1 month;
* oral, topical, intramuscular testosterone preparations.
* Illicit drug use, including amphetamines, cocaine, or heroin, within the last 6 months. Marijuana use is not exclusionary.
* Chronic smokers and subjects who use smokeless tobacco products (due to known effects of tobacco on the oral microbiome).
* Claustrophobia.
* Use of antacids (proton pump inhibitors, sucralfate, H1 and H2 antagonists, and those containing aluminum magnesium) within the last 3 months.
* Use of laxatives or enemas within the last 3 months.
* Diagnostic colonoscopy within the last 6 months.
* Use of topical antibiotics or topical steroids on the face, scalp, or neck, or on arms, forearms, or hands within the previous 30 days.
* Use of vaginal/vulvar medications, including antifungals, within the previous 30 days. Subjects may continue to use permitted vaginal contraceptives (spermicides and female condoms) until 24 hours prior to sampling
* Use of isotretinoin within the past 5 years.
* Intranasal influenza vaccination within the last 6 months due to effects on mucosal immunity.
* Acute disease at the time of enrollment (defer enrollment until subject recovers). Acute disease is defined as the presence of a moderate or severe illness with or without fever.
* Chronic, clinically significant (unresolved, requiring ongoing medical management or medication) pulmonary, cardiovascular, dermatologic, endocrine, GI, hepatic, or renal functional abnormality, as determined by medical history, physical examination, and/or laboratory testing. Includes, but not limited to:
* A history of diabetes mellitus (Type 1 or 2), pituitary disease, hypothyroidism, hyperthyroidism
* A history of physician-diagnosed asthma
* A history of allergy to any antibiotic medications, including amoxicillin (penicillin) and/or azithromycin (macrolide)
* A history of food allergy requiring dietary accommodation
* Lactose-intolerance requiring dietary accommodation
* A history of a bleeding disorder
* Mononucleosis
* Liver disease, including non-alcoholic fatty liver disease, AST or ALT \> 1.5 times normal value, cirrhosis
* Renal disease, as defined by serum creatinine concentrations \> 1.5 mg/dL and/or overt proteinuria
* Central nervous system disease, including previous history of cerebrovascular accidents, dementia, and neurodegenerative disorders
* Clinically significant abnormal results on electrocardiogram (ECG) that in the opinion of the PI, would place the patient at increased risk of QT-prolongation or other cardiac event
* Genitourinary/Gynecologic conditions, including:
* Treatment for or suspicion of ever having had toxic shock syndrome
* History of hysterectomy or oophorectomy
* History of condyloma or human papillomavirus diagnosed within the previous 2 years
* History of candidiasis, urinary tract infection, or sexually transmitted disease (specifically chlamydia, gonorrhea, syphilis, genital herpes, trichomoniasis) diagnosed within the previous 6 months
* Evidence (by history or physical exam) of vulvar or vaginal irritation at screening
* History of vulvar, vaginal, or cervical dysplasia within the previous 5 years
* History of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.
* Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
* Recent history of excessive alcohol consumption defined as more than five 1.5-ounce servings of 80-proof distilled spirits, five 12-ounce servings of beer, or five 5-ounce servings of wine at one sitting over the last 30 days.
* Positive test for HIV, hepatitis B virus, or hepatitis C virus indicating infection (hepatitis B seropositivity conferred by vaccination is not exclusionary).
* Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired).
* Major surgery of the GI tract, including cholecystectomy or appendectomy, in the past 5 years. Any major bowel resection at any time.
* History of gastric stapling, lap band, or surgical procedure for treatment of obesity.
* History of GI disorders or diseases including:
* inflammatory bowel disease (IBD) including ulcerative colitis, Crohn s disease (of any severity), or indeterminate colitis;
* irritable bowel syndrome (IBS);
* persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent), gastric or duodenal ulcer;
* Celiac disease;
* chronic constipation.
* Active behavioral or psychiatric conditions that would be incompatible with a safe and successful participation in the study, including major depression, anxiety disorder, schizophrenia, and presence of psychotic symptoms.
* Active eating disorders, including anorexia nervosa, bulimia, or binge eating syndrome.
* Use of weight-loss drugs within the past 5 years.
* Weight change (intended or unintended; loss or gain) of more than 10% of total body weight in the 3 months before admission.
* Regular urinary incontinence necessitating use of incontinence protection garments.
* Female who is pregnant, intending to become pregnant, or lactating.
* History of recurrent rashes within the past 6 months.
* At the time of the screening visit:
* multiple blisters, pustules, boils, abscesses, erosions or ulcers on the scalp, face, neck, arms, forearms, or hands;
* uniformly thickened, cracking, dry skin on bilateral palms and/or soles;
* disseminated rash (at multiple body sites or extending throughout a broad body area).
* Subjects who are unable to complete required study visits per allotted visit windows.
* Any condition that, in the opinion of the investigator, contraindicates participation in this study.
